

MESOTHELIOMA TREATMENT REGIMENS (Part 1 of 2)

Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment.

Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies.

These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

First-line Combination¹

Note: All recommendations are Category 2A unless otherwise indicated.

REGIMEN	DOSING
Pemetrexed + cisplatin (Category 1)²	Day 1: Pemetrexed 500mg/m ² IV day 1 followed 30 minutes later by cisplatin 75mg/m ² over 2 hours. Repeat every 21 days up to 12 cycles.
Pemetrexed + cisplatin + bevacizumab (Category 1)^{10,a}	Day 1: Pemetrexed 500mg/m ² IV + cisplatin 75mg/m ² IV + bevacizumab 15mg/kg IV. Repeat every 21 days for 6 cycles, followed by: Maintenance bevacizumab 15mg/kg every 21 days until disease progression.
Pemetrexed + carboplatin^{3-5,c}	Day 1: Pemetrexed 500mg/m ² IV and carboplatin AUC 5mg·min/mL IV. Repeat every 21 days for a max of 9 cycles.
Gemcitabine + cisplatin^{6,7}	Day 1: Cisplatin 80–100mg/m ² IV over 1 hour Days 1, 8, and 15: Gemcitabine 1000–1250mg/m ² IV over 30 minutes. Repeat every 21–28 days for 6 cycles.
Pemetrexed⁸	Day 1: Pemetrexed 500mg/m ² IV. Repeat every 21 days for 4 cycles.
Vinorelbine⁹	Vinorelbine 25–30mg/m ² (max 60mg) IV every week for 12 weeks.

Subsequent Systemic Therapy⁴

Pemetrexed (if not administered as first-line) (Category 1)^{11,12b}	Day 1: Pemetrexed 500mg/m ² IV. Repeat every 3 weeks for 8 cycles.
Vinorelbine^{13,14}	Vinorelbine 30mg/m ² (max 60mg) IV weekly. Repeat every 6 weeks for 11 cycles.
Gemcitabine¹⁴⁻¹⁶	Days 1, 8, and 15: Gemcitabine 1250mg/m ² IV. Repeat every 28 days for a max of 10 cycles.
Nivolumab ± ipilimumab¹⁷	Day 1: Nivolumab 3mg/kg IV over 1 hour every 2 weeks Day 1: Ipilimumab 1mg/kg IV over 1.5 hours every 6 weeks. Repeat until disease progression or unacceptable toxicity.
Pembrolizumab¹⁸	Day 1: Pembrolizumab 10mg/kg IV every 2 weeks. Repeat for 2 years or until disease progression or unacceptable toxicity.

^a The combination regimen of pemetrexed + cisplatin + bevacizumab is only for unresectable disease.

^b Consider rechallenge if good sustained response at the time initial chemotherapy was interrupted.

^c The carboplatin/pemetrexed regimen is recommended for patients with poor performance score and/or comorbidities.

References

- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Malignant Pleural Mesothelioma. V2.2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf. Accessed December 18, 2017.
- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol.* 2003;21:2636–2644.
- Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma. *Ann Oncol.* 2008;19:370–373.
- Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. *J Clin Oncol.* 2006;24:1443–1448.
- Santoro A, O'Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemo-naïve patients with malignant pleural mesothelioma. *J Thorac Oncol.* 2008;3:756–763.
- Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. *Br J Cancer.* 2002;87:491–496.
- Van Haarst JM, Baas J, Manegold CH, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. *Br J Cancer.* 2002; 86:342–345.
- Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemo-naïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. *J Thorac Oncol.* 2008;3:764–771.
- Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. *Lancet.* 2008;371:1685–1694.
- Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. *Lancet.* 2015;387(10026):1405–1414.
- Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. *J Clin Oncol.* 2008;26:1698–1704.

continued

MESOTHELIOMA TREATMENT REGIMENS (Part 2 of 2)

References (continued)

12. Zucal PA, Simonelli M, Michetti G, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. *Lung Cancer*. 2012;75: 360-367.
13. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. *Lung Cancer*. 2009;63:94-97.
14. Zauderer MG, Kass SL, Woo K, et al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. *Lung Cancer*. 2014;84:271-274.
15. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. *Ann Oncol*. 2005; 16:923-927.
16. van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. *Cancer*. 1999;85: 2577-2582.
17. Scherpereel A, Mazieres J, Greiller L, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase 2 trial [abstract]. *J Clin Oncol*. 2017;35: Abstract LBA8507.
18. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomized, open-label, phase 1b trial. *Lancet Oncol*. 2017; 18:623-630.

(Revised 12/2017)

© 2017 Haymarket Media, Inc.